Cargando…

Real‐world outcomes of niraparib treatment in patients with ovarian cancer: a multicenter non‐interventional study in China

Detalles Bibliográficos
Autores principales:	Li, Jin, Yang, Jianhua, Shou, Huafeng, Zhang, Lin, Huang, Xiaohong, Tang, Xuedong, Zheng, Fei, Liu, Fang, Wen, Hao, Yang, Huijuan, Wang, Huaying, Li, Ziting, Chen, Xiaojun, Ju, Xingzhu, Cheng, Xi, Tang, Jie, Zhang, Meiqin, Wu, Xiaohua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259665/ https://www.ncbi.nlm.nih.gov/pubmed/37040265 http://dx.doi.org/10.1002/cac2.12418

Ejemplares similares

Niraparib for ovarian cancer
Publicado: (2021)

How to start niraparib in real-world Asian ovarian cancer patients?
por: Hong, Sook-Hee
Publicado: (2021)

Rucaparib and Niraparib in Advanced Ovarian Cancer
por: Redelico, Tyler
Publicado: (2019)

Efficacy and Safety of Niraparib as First-Line Maintenance Treatment for Patients with Advanced Ovarian Cancer: Real-World Data from a Multicenter Study in China
por: Zhao, Minmin, et al.
Publicado: (2023)

Safety and management of niraparib monotherapy in ovarian cancer clinical trials
por: Monk, Bradley J, et al.
Publicado: (2023)

Pharmacological effects of Niraparib and its combination with angiogenic inhibitor in ovarian cancer
por: Liu, Huiwen, et al.
Publicado: (2023)

Case Report: Niraparib as Maintenance Therapy in A Patient With Ovarian Carcinosarcoma
por: Zhang, Jie Qing, et al.
Publicado: (2021)

Niraparib in ovarian cancer: results to date and clinical potential
por: Caruso, Davide, et al.
Publicado: (2017)

Conization Using an Electrosurgical Knife for Cervical Intraepithelial Neoplasia and Microinvasive Carcinoma
por: Xiang, Libing, et al.
Publicado: (2015)

Real-world hematological adverse events in Chinese patients with advanced ovarian cancer treated with an individualized starting dose of niraparib
por: Wang, Junjian, et al.
Publicado: (2021)

Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment
por: Akce, Mehmet, et al.
Publicado: (2021)

Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical Trial
por: Li, Ning, et al.
Publicado: (2023)

Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer
por: Lee, Arnold
Publicado: (2021)

Niraparib and Advanced Ovarian Cancer: A Beacon in the Non-BRCA Mutated Setting
por: Maiorano, Mauro Francesco Pio, et al.
Publicado: (2023)

Cost-effectiveness of maintenance niraparib with an individualized starting dosage in patients with platinum-sensitive recurrent ovarian cancer in China
por: Shi, Yin, et al.
Publicado: (2023)

Distal pancreatectomy with splenectomy for the management of splenic hilum metastasis in cytoreductive surgery of epithelial ovarian cancer
por: Xiang, Libing, et al.
Publicado: (2016)

An In-Depth Review of Niraparib in Ovarian Cancer: Mechanism of Action, Clinical Efficacy and Future Directions
por: Akay, Melek, et al.
Publicado: (2021)

Correction to: Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer
por: Lee, Arnold
Publicado: (2021)

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib
por: Guo, Menglin, et al.
Publicado: (2022)

Addendum: A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study
por: Shi, Tingyan, et al.
Publicado: (2022)

The efficacy and safety of niraparib for ovarian cancer: a single-center observational study from China
por: Ni, Jing, et al.
Publicado: (2021)

Safety Profile of Niraparib as Maintenance Therapy for Ovarian Cancer: A Systematic Review and Meta-Analysis
por: Pagkali, Antonia, et al.
Publicado: (2022)

Cost-Effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum-Sensitive Recurrent Ovarian Cancer
por: Zhong, Lixian, et al.
Publicado: (2018)

Preoperative Neutrophil-to-Lymphocyte Ratio as a Predictive and Prognostic Factor for High-Grade Serous Ovarian Cancer
por: Feng, Zheng, et al.
Publicado: (2016)

The preoperative prognostic nutritional index is a predictive and prognostic factor of high-grade serous ovarian cancer
por: Feng, Zheng, et al.
Publicado: (2018)

Hormone receptor expression profiles differ between primary and recurrent high-grade serous ovarian cancers
por: Feng, Zheng, et al.
Publicado: (2017)

Niraparib exhibits a synergistic anti-tumor effect with PD-L1 blockade by inducing an immune response in ovarian cancer
por: Meng, Jinyu, et al.
Publicado: (2021)

The prognosis of women with stage IB1-IIB node-positive cervical carcinoma after radical surgery
por: Cheng, Xi, et al.
Publicado: (2004)

A clinically applicable molecular classification for high-grade serous ovarian cancer based on hormone receptor expression
por: Feng, Zheng, et al.
Publicado: (2016)

Expression of hypothalamic-pituitary-gonadal axis-related hormone receptors in low-grade serous ovarian cancer (LGSC)
por: Feng, Zheng, et al.
Publicado: (2017)

A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study
por: Shi, Tingyan, et al.
Publicado: (2020)

Homologous recombination repair gene mutations show no survival benefits in Chinese high-grade serous ovarian cancer patients
por: Feng, Zheng, et al.
Publicado: (2021)

Risk-reducing salpingo-oophorectomy among Chinese women at increased risk of breast and ovarian cancer
por: Feng, Zheng, et al.
Publicado: (2023)

Case Report: Niraparib-Related Pulmonary Embolism During the Treatment of BRCA Mutant Advanced Ovarian Cancer
por: Wei, Qiang, et al.
Publicado: (2022)

A phase 1 evaluation of the safety and tolerability of niraparib in combination with everolimus in advanced ovarian and breast cancers
por: Starks, David, et al.
Publicado: (2023)

Effectiveness and Safety of Niraparib as Neoadjuvant Therapy in Advanced Ovarian Cancer With Homologous Recombination Deficiency (NANT): Study Protocol for a Prospective, Multicenter, Exploratory, Phase 2, Single-Arm Study
por: Zhou, Dongchen, et al.
Publicado: (2022)

Niraparib-induced STAT3 inhibition increases its antitumor effects
por: Zhao, Qianqian, et al.
Publicado: (2022)

Short-term starvation synergistically enhances cytotoxicity of Niraparib via Akt/mTOR signaling pathway in ovarian cancer therapy
por: Zhi, Wang, et al.
Publicado: (2022)

Curcumol Targeting PAX8 Inhibits Ovarian Cancer Cell Migration and Invasion and Increases Chemotherapy Sensitivity of Niraparib
por: Liu, Caihong
Publicado: (2022)

Correction to: Short‑term starvation synergistically enhances cytotoxicity of Niraparib via Akt/mTOR signaling pathway in ovarian cancer therapy
por: Wang, Zhi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_691iffeu7pk8meudb79mpnm3g1